Aurobindo Pharma has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Pioglitazone Tablets USP 15mg, 30mg & 45mg (ANDA 200268) and its earlier tentatively approved Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets, 15mg (base)/500mg & 15mg (base)/850mg (ANDA 200823). The products are ready for launch.
Pioglitazone Tablets USP 15mg, 30mg, 45mg and Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets, 15mg(base)/500mg, 15mg(base)/850mg are the generic equivalents of Takeda Global Research Development Center Inc’s Actos Tablets 15mg, 30mg, 45mg and Actoplus Met Tablets, 15mg (base)/500mg, 15mg (base)/850mg respectively.
The products are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. The combined market size of the products is about $2.8 billion for the twelve months ending September 2012.
Aurobindo now has a total of 177 ANDA approvals (152 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: